Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease, Musculoskeletal Disorders and Oncology is under clinical development by Hope Biosciences and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease, Musculoskeletal Disorders and Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease, Musculoskeletal Disorders and Oncology overview
Cell therapy is under development for the treatment of hip osteoarthritis, traumatic brain injury, cerebral palsy, relapsing remitting multiple sclerosis (RRMS), rheumatoid arthritis, spinal cord injury (C5-C7 level), LMNA-related congenital muscular dystrophy (L-CMD), multiple sclerosis Parkinson's disease, chronic musculoskeletal pain, coronavirus disease 2019 (COVID-19), amyotrophic lateral sclerosis and primary lateral sclerosis. The drug candidate comprises of autologous adipose derived mesenchymal stem cells. It was also under development for systemic lupus erythematosus (SLE), prostate cancer, glioblastoma multiforme (GBM), pancreatic cancer, stroke and Huntington disease and Alzheimer's disease.
Hope Biosciences overview
Hope Biosciences is a biopharmaceutical company that offers mesenchymal stem cell culture products and services for adults and newborns. Hope Biosciences is headquartered in Sugar Land, Texas, the US.
For a complete picture of Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease, Musculoskeletal Disorders and Oncology’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
